Text Size

Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer (MRSI+RRP)

This study is currently recruiting participants.
Verified January 2013 by OHSU Knight Cancer Institute
Sponsor:
Collaborators:
Department of Defense
Portland VA Medical Center
Oregon Health and Science University
Information provided by (Responsible Party):
OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier:
NCT01780701
First received: January 7, 2013
Last updated: January 29, 2013
Last verified: January 2013
History of Changes
  Purpose

A prostate cancer diagnosis starts a list of events that often leads to fast-moving treatment, thought by many to result in vast over-treatment of this disease. So, discovery of different diagnostic methods that allow clinicians to identify slow-growing from potentially fast-growing disease prior to or at the time of prostate biopsy could result in early and suitable treatment for men at greatest risk, while greatly decreasing the number of biopsies, surgical procedures, hormonal and chemotherapeutic treatments, cost, and patient worry, for those with more slow-growing disease.


Condition Intervention
Prostate Cancer
 Procedure: Magnetic Resonance Spectroscopy Imaging with rectal probe

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Imaging Prostatic Lipids to Distinguish Aggressive Prostate Cancer

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by OHSU Knight Cancer Institute:

Primary Outcome Measures:
  • Number of participants with increased intraprostatic lipid concentration [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
    Determine the correlation between the amount of intraprostatic lipid using 1H magnetic resonance spectroscopic imaging (MRSI) with an endorectal coil obtained prior to prostatectomy with fatty acid synthase protein expression measured in benign and cancer tissue from prostatectomy samples.


Secondary Outcome Measures:
  • Number of participants with increased tumor aggressiveness [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
    Identify the association between fatty acid synthase protein expression in prostatectomy samples, intraprostatic lipid as measured by 1H MRSI, and prostate tumor aggressiveness.


Other Outcome Measures:
  • Number of participants with accumulation of lipid intermediates and proteins [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
    To quantify the association between key metabolic intermediates involved in lipid metabolism, mitochondrial function, inflammation, and apoptosis in prostatectomy samples and fatty acid synthase protein expression, intraprostatic lipid and tumor aggressiveness.


Biospecimen Retention:   Samples Without DNA

Blood, Urine, Prostatic fluid and prostatectomy tissue


Estimated Enrollment: 105
Study Start Date: January 2013
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
High risk prostate cancer patients
Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
 Procedure: Magnetic Resonance Spectroscopy Imaging with rectal probe
Other Name: MRSI
Low risk prostate cancer patients
Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 [3+4] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
 Procedure: Magnetic Resonance Spectroscopy Imaging with rectal probe
Other Name: MRSI

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

all men newly-diagnosed with prostate cancer at the Portland VA Urology clinic

Criteria

Inclusion Criteria:

  • Prostate cancer diagnosis prior to treatment
  • Age 21 years or older
  • Signed informed subject consent
  • Prostatectomy as planned prostate cancer treatment

Exclusion Criteria:

  • Men who do not choose prostatectomy
  • Men who have undergone any neoadjuvant therapy
  • Men who have cardiac pacemakers or other implanted electronic devices
  • Men who have any surgically implanted metal
  • Men who have had any surgical procedure that precludes placement of endorectal probe
  • Indication of dementia or memory issues listed on problem list
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01780701

Contacts
Contact: Jackilen Shannon, PhD 503-220-8262 ext 57285 shannoja@ohsu.edu
Contact: Paige E Farris, MSW 503-220-8262 ext 54868 farrisp@ohsu.edu

Locations
United States, Oregon
Portland VA Medical Center Recruiting
Portland, Oregon, United States, 97207
Principal Investigator: Jackilen Shannon, PhD            
Sub-Investigator: Mark Garzotto, MD            
Sub-Investigator: George Thomas, MD            
Oregon Health & Science University Advanced Imaging Research Center Recruiting
Portland, Oregon, United States, 97239
Principal Investigator: Jonathan Q Purnell, MD            
Sub-Investigator: William Rooney, PhD            
Sub-Investigator: Xin Li, PhD            
Sponsors and Collaborators
OHSU Knight Cancer Institute
Department of Defense
Portland VA Medical Center
Oregon Health and Science University
Investigators
Principal Investigator: Jackilen Shannon, PhD Oregon Health and Science University
Principal Investigator: Jonathan Q Purnell, MD Oregon Health and Science University
  More Information

No publications provided

Responsible Party: OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier: NCT01780701     History of Changes
Other Study ID Numbers: PC110361/ PC110361P1, W81XWH-12-1-0168, 2978, 8458, Log #A-17208
Study First Received: January 7, 2013
Last Updated: January 29, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by OHSU Knight Cancer Institute:
prostate cancer aggressiveness
magnetic resonance imaging
fatty acid synthase

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
 Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on May 23, 2013